Yes. By lowering prolactin levels, Dostinex can restore normal ovulation, improving the chances of conception for women whose infertility is linked to hyperprolactinaemia.
Many women see a return to regular cycles within 4-8 weeks, though individual response varies and follow-up prolactin testing guides treatment adjustments.
Sit or lie down immediately, hydrate, and rise slowly from a seated position. If dizziness persists or is severe, contact your healthcare provider for evaluation.
No specific food prohibitions exist, but consistent timing with meals helps maintain steady drug absorption. Limit excessive alcohol, which can exacerbate dizziness.
Yes, provided you carry the medication in its original labelled container, have a copy of the prescription, and declare it if required by the destination country’s customs regulations.
Dostinex (cabergoline) has a longer half-life, allowing twice-weekly dosing, and is generally better tolerated with fewer gastrointestinal side effects compared with bromocriptine, which typically requires daily dosing.
Cabergoline may lower blood pressure, so co-administration with antihypertensives warrants monitoring. Dose adjustments of either medication may be necessary under medical supervision.
In the UK, 0.25 mg tablets are round, white, and embossed with “0.25 mg” on one side; 0.5 mg tablets are round, pink, and marked “0.5 mg.” (Exact imprint may vary by manufacturer.)
Generic cabergoline typically offers a lower price point than the branded product, though pricing depends on pharmacy dispensing policies and NHS reimbursement structures. Patients should discuss cost options with their prescriber or pharmacist.
Dostinex is a brand-name medication that contains the active ingredient cabergoline. It is formulated as an oral pill and is available in the United Kingdom in strengths of 0.25 mg and 0.5 mg. Cabergoline belongs to the class of dopamine-receptor agonists and is primarily prescribed to treat conditions caused by excess prolactin, a hormone produced by the pituitary gland. In the UK, Dostinex is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Cabergoline mimics the action of dopamine, a neurotransmitter that naturally inhibits prolactin secretion. By binding to dopamine-type 2 (D₂) receptors on pituitary lactotroph cells, cabergoline reduces the release of prolactin into the bloodstream. Lower prolactin levels help restore normal menstrual cycles, improve fertility, and alleviate symptoms such as galactorrhoea (unexpected breast milk production).
Key pharmacologic features:
In the United Kingdom, Dostinex is licensed for the treatment of hyperprolactinaemia in both men and women. The approval covers:
The medication may also be prescribed for pituitary adenomas that secrete prolactin, when surgery is not appropriate or as adjunct therapy.
Cabergoline has been investigated for several off-label indications. The most notable is its use in Parkinson’s disease, where its dopaminergic activity can help control motor symptoms. This application is not approved by the MHRA for Dostinex, and any off-label use should be supervised by a neurologist familiar with the risk-benefit profile.
Disclaimer: Off-label use requires individualized medical supervision and a careful risk assessment.
Who Should Use Dostinex?
Absolute Contraindications
Relative Contraindications
Special Populations
Special Populations
Administration Tips
Overdose Management
Discontinuation
This article provides educational information about Dostinex (cabergoline) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
